🇵🇹 Daily Portugal news for expats & investors — FREE Subscribe
Sign in Subscribe

Infarmed

Infarmed Pulls 53 FBeauty Cosmetic Lines Off the Market After a Complaint-Triggered Inspection Flags Four EU 1223/2009 Breaches — Circular 059/CD/550.20.001 Suspends Sales as Consumers Are Told to Stop Use

Infarmed Pulls 53 FBeauty Cosmetic Lines Off the Market After a Complaint-Triggered Inspection Flags Four EU 1223/2009 Breaches — Circular 059/CD/550.20.001 Suspends Sales as Consumers Are Told to Stop Use

Infarmed Circular 059/CD/550.20.001 of 5 June 2026 orders the immediate withdrawal of 53 FBeauty cosmetic products after a complaint-triggered inspection flagged four breaches of EU Regulation 1223/2009 — covering GMP, safety assessment, product information file and labelling.
The Portugal Brief
Infarmed Reads SNS Medicine Spend at a Record €4.417 Billion in 2025 — Hospital Drugs Cross €2.5 Billion for the First Time as Oncology Adds €864.5 Million at +16% and Ambulatory Comparticipação Lifts to €1.894 Billion at +12.4%

Infarmed Reads SNS Medicine Spend at a Record €4.417 Billion in 2025 — Hospital Drugs Cross €2.5 Billion for the First Time as Oncology Adds €864.5 Million at +16% and Ambulatory Comparticipação Lifts to €1.894 Billion at +12.4%

Infarmed's 2025 monitor puts SNS medicine spending at a record €4,417M — +60% above the 2020 baseline. Hospitals carry €2,523M (+11.2%), ambulatory €1,894M (+12.4%), families €966M (+4.9%). Oncology adds €864.5M (+16%), orphan drugs +34.1%, and Q1 2026 hospitals already +7.6%.
The Portugal Brief
Sociedade Portuguesa de Diabetologia and the Ordem dos Médicos Demand Infarmed Revoke the 13 April Glucose-Sensor Circular — Generic Prescription Treats Two Medical Devices With Different Age Approvals and Different Apps as Interchangeable

Sociedade Portuguesa de Diabetologia and the Ordem dos Médicos Demand Infarmed Revoke the 13 April Glucose-Sensor Circular — Generic Prescription Treats Two Medical Devices With Different Age Approvals and Different Apps as Interchangeable

SPD president Estevão Pape and Ordem dos Médicos bastonário Carlos Cortes call Infarmed's 13 April circular a 'clinical setback'. The shift from brand-specific to generic prescription treats two CGM sensors as interchangeable — but one is approved age 2+, the other age 18+, and the apps don't talk.
The Portugal Brief